The beginning of a phase I clinical trial of the drug from SARS-CoV-2

1 December 2020

CPD has started a phase I clinical trial of an innovative drug — human immunoglobulin containing antibodies against SARS-CoV-2.

Back to the list

A phase I study of an innovative drug used in the treatment of patients with a new coronavirus infection (COVID-19) has been completed. The final report has been prepared.

CPD has developed a strategy for preclinical and clinical study of a new prolonged finished dosage form in order to further obtain a registration certificate.

Subscribe to the newsletter of interesting articles and news